Arcus Biosciences Toekomstige groei

Future criteriumcontroles 1/6

Arcus Biosciences zal naar verwachting groeien in winst en omzet met respectievelijk 3.9% en 18.5% per jaar. De winst per aandeel zal naar verwachting groeien met 9.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -88.3% zijn.

Belangrijke informatie

3.9%

Groei van de winst

9.4%

Groei van de winst per aandeel

Biotechs winstgroei	28.3%
Inkomstengroei	18.5%
Toekomstig rendement op eigen vermogen	-88.3%
Dekking van analisten	Good
Laatst bijgewerkt	08 Nov 2024

Recente toekomstige groei-updates

Recent updates

Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 15

Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Aug 19

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31

Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO

May 15

Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

May 13

Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

May 10

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

Mar 20

What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Feb 23

Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment

Feb 22

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Dec 18

Arcus Biosciences: Showing There Might Be Something To TIGIT After All

Dec 15

Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Nov 30

Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey

Nov 20

Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data

Aug 29

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Aug 08

Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates

Jun 15

Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

May 05

Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17

Nov 02

Winst- en omzetgroeiprognoses

NYSE:RCUS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	251	-417	-224	-250	9
12/31/2025	217	-386	-453	-361	10
12/31/2024	260	-303	-153	-269	10
9/30/2024	263	-270	-169	-158	N/A
6/30/2024	247	-249	-267	-247	N/A
3/31/2024	237	-231	-235	-210	N/A
12/31/2023	117	-307	-330	-306	N/A
9/30/2023	120	-293	-306	-288	N/A
6/30/2023	121	-287	-316	-306	N/A
3/31/2023	119	-279	-326	-314	N/A
12/31/2022	112	-267	426	438	N/A
9/30/2022	433	80	426	446	N/A
6/30/2022	409	67	447	473	N/A
3/31/2022	392	58	439	464	N/A
12/31/2021	383	53	-282	-256	N/A
9/30/2021	38	-278	-263	-244	N/A
6/30/2021	93	-199	14	26	N/A
3/31/2021	85	-168	70	76	N/A
12/31/2020	78	-123	108	111	N/A
9/30/2020	78	-88	150	152	N/A
6/30/2020	15	-112	-93	-92	N/A
3/31/2020	15	-95	-89	-88	N/A
12/31/2019	15	-85	-75	-73	N/A
9/30/2019	7	-80	-73	-71	N/A
6/30/2019	9	-69	-58	-55	N/A
3/31/2019	9	-54	-50	-47	N/A
12/31/2018	8	-50	-47	-43	N/A
9/30/2018	8	-51	-24	-20	N/A
6/30/2018	4	-63	N/A	-33	N/A
3/31/2018	3	-59	N/A	-29	N/A
12/31/2017	1	-53	N/A	-25	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat RCUS de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat RCUS de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat RCUS de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van RCUS ( 18.5% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van RCUS ( 18.5% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat RCUS binnen 3 jaar verliesgevend zal zijn.

Arcus Biosciences Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates decrease by 11%

Price target decreased by 11% to US$34.44

Consensus revenue estimates increase by 52%

Consensus revenue estimates increase by 35%, EPS downgraded

Price target decreased by 7.9% to US$39.70

Price target decreased to US$50.10

Recent updates

Arcus Biosciences, Inc.'s (NYSE:RCUS) Price Is Right But Growth Is Lacking

Now 24% undervalued after recent price drop

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arcus Biosciences, Inc. Announces Domvanalimab Plus Zimberelimab Improved Overall Survival in Arc-10, A Randomized Study in Patients with Pd-L1-High Non-Small Cell Lung Cancer

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Arcus Biosciences: Advancing On Several Fronts

Arcus Biosciences, Inc. Announces Arcus Biosciences’ HIF-2A Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Now 21% undervalued

Arcus Biosciences, Inc. to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Insufficient new directors

Arcus Biosciences, Inc. announced that it expects to receive $250 million in funding

Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates decrease by 11%

Price target decreased by 11% to US$34.44

Arcus Biosciences, Inc.(NYSE:RCUS) dropped from Russell 2500 Value Index

New major risk - Revenue and earnings growth

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO

Consensus revenue estimates increase by 52%

Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

Arcus Biosciences, Inc. Reports Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2024

Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

Arcus Biosciences, Inc. Reports Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arcus Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer recently sold US$241k worth of stock

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

Chief Operating Officer notifies of intention to sell stock

Consensus revenue estimates increase by 35%, EPS downgraded

What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment

Price target decreased by 7.9% to US$39.70

Arcus Biosciences, Inc. Announces Data from A Phase 1B Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naive Metastatic Pancreatic Cancer

Co-Founder notifies of intention to sell stock

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Co-Founder notifies of intention to sell stock

Arcus Biosciences: Showing There Might Be Something To TIGIT After All

Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Arcus Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Insufficient new directors

COO & Director notifies of intention to sell stock

Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Arcus Biosciences, Inc. to Report Q2, 2023 Results on Aug 07, 2023

New minor risk - Shareholder dilution

Arcus Biosciences, Inc. announced that it expects to receive $19.4526 million in funding from Gilead Sciences, Inc.

COO & Director notifies of intention to sell stock

COO & Director recently sold US$243k worth of stock

COO & Director notifies of intention to sell stock

Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates

Arcus Biosciences, Inc. Provides Updated Results from an Interim Analysis of ARC-7

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

COO & Director recently sold US$147k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Arcus Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023